To The Moon

$Luckin Coffee Inc.(LKNCY)$   Strong Financial Performance Luckin Coffee has demonstrated remarkable financial growth in recent years. For 2024, the company’s revenue was estimated at approximately $4.86 billion, reflecting a significant increase compared to prior years. This consistent growth highlights Luckin Coffee’s expanding market presence and increasing consumer demand, positioning the company as a strong player in the coffee industry. Market Expansion Luckin Coffee is actively broadening its reach both domestically in China and internationally. Recently, the company secured a multi-billion RMB deal to procure Brazilian coffee beans, ensuring a steady supply of premium-quality beans. This move not only fortifies its supply chain

Why I Buy Tiger Shares and Sell Covered Calls for Steady Returns 🐯💵 Tiger Brokers (TIGR) shares present an excellent opportunity for earning steady income through covered call strategies. Here’s why: 1. Strong Short-Term Premiums 💹 Selling covered calls on Tiger shares allows me to earn a solid return. In the current example, I’m earning over 3% in just two weeks from call premiums while maintaining the ability to adjust my strategy based on market movements. These premiums represent a high annualized yield with minimal risk since I already own the underlying shares. 2. Stable Stock Price 🔒 Tiger’s stock price has shown resilience, hovering around $6.50 to $6.72, which provides a perfect scenario for covered call selling. If the stock price stays at or above my call strike prices, I can ei

A new year, a new beginning and an opportunity for investors to reassess their financial strategies and safeguard their wealth. All in the face of : Looming economic uncertainty (with a new US administration). Possibility of inflation ticking back up and eroding purchasing power of traditional currencies. Other challenges on the horizon. There are a few different assets that can be called upon to preserve wealth. Gold is a worthy consideration. The precious metal can be leveraged to: Hedge against inflation. Diversify portfolios. Build a foundation for long-term financial security.  Good news is there’s a wide range of gold assets to choose from, including gold bullion. Selecting the right type to invest in, can be daunting, especially for first timer. For a start, understand the phys

$Merck(MRK)$ Merck, trading under the ticker symbol MRK, is currently priced at $99.50 per share. Over the past six months, the stock has experienced a 27% decline, reflecting significant pressure. Despite this, Merck boasts a robust product portfolio, including blockbuster drugs that are key revenue drivers. These products have strong market shares and considerable long-term growth potential. Today, we’ll analyze Merck using my automated stock valuation spreadsheet. We'll employ models like the Discounted Free Cash Flow (DCF), Comparable Company Analysis, Dividend Discount Model (DDM), and Ben Graham's Intrinsic Value Formula to determine whether Merck is a buy or sell. Earning Overview In the third quarter of 2024, Merck & Co., Inc. reported

The stock market started off the first trading day of 2025 on a positive note, the rise was due to buy-the-dip trading and rebalancing activities. But soon, we saw the stock market faced volatility during the first session of the year as major U.S. equities indexes reversed course in the afternoon to end the session lower. Rising interest rates and losses in large-cap stocks caused a midday decline. Despite this volatility, the market closed above session lows with minimal losses. The S&P 500 fell 0.2% after initial peak at 0.9% gain on Thursday, extending a streak of down days dating back to last week's return from the Christmas holiday. NASDAQ managed 1.1% intraday high before settling for a 0.2% decline. DJIA slipped 0.36% following this Wednesday's New Year's Day pause, Russell 200

As markets experience inevitable pullbacks, many investors find themselves caught in the dilemma of timing the market. Should you sell at the highs, or is this an opportune moment to buy? While the debate is perennial, the wisdom of legendary investors like Peter Lynch provides a timeless perspective: time in the market beats timing the market. Let’s explore this principle and how it shapes long-term investment strategies. The Peter Lynch Philosophy: Time in Market Beats Timing the Market Peter Lynch, one of the most successful investors of all time, famously stated, "Far more money has been lost by investors preparing for corrections than in the corrections themselves." This underscores the value of staying invested through market cycles. The concept is simple: Timing the market requires

We are still not seeing strong volume from Bitcoin trading, the price of bitcoin is holding above the $96,000 mark as traders adopt a cautious approach. Funding rates remain subdued as the cryptocurrency market begins the year. Cautious Approach Ahead Of Jan 20 Inauguration $CME Bitcoin - main 2501(BTCmain)$ is currently holding above $96,000, with analysts attributing its stability to traders' cautious approach ahead of potential market-moving events, including Donald Trump's inauguration on Jan. 20. The bitcoin perpetual futures funding rate stands at 0.01%, per the most recent 8-hour contract cycle across most major exchanges, according to Coinglass data. This is the highest in over one week but still within a neutral range, according to B

$Pfizer(PFE)$ $Biogen(BIIB)$ $Novo-Nordisk A/S(NVO)$ $Johnson & Johnson(JNJ)$ Pharmaceutical companies is a favorite among the dividend investment community. During the pandemic, the company often reminded us that we were heroes. Meanwhile, on social media, people were labeling Pharmaceutical as "evil" due to conspiracy theories about vaccine containing microchips. What a time to be alive! In this article, I’ll explain why not to invest in pharmaceutical companies. But before diving in, let’s consider what the most renowned investors tend to look for in their portfolios. Legendary investors favor companies with competit